Related Experiment Video
Updated: May 21, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Case series of type III hyperlipoproteinemia in children
Michelle Fung1, John Hill, Donald Cook
1University of British Columbia, Vancouver, British Columbia, Canada. michelle.fung@vch.ca
Insights
Type III hyperlipoproteinemia (HLP) in children is rare but serious, leading to lifelong vascular disease and pancreatitis. Early intervention with medication may be necessary if diet alone is insufficient.
Area of Science:
- Cardiology
- Genetics
- Metabolic Disorders
Background:
- Type III hyperlipoproteinemia (HLP) is a rare genetic lipid disorder.
- Pediatric onset of Type III HLP is exceptionally uncommon.
Observation:
- A long-term follow-up of three pediatric patients with Type III HLP was conducted.
- Patients presented with severe complications including hypothyroidism, palmar xanthomas, splenomegaly, recurrent pancreatitis, and premature coronary artery disease.
Findings:
- Genetic analysis revealed an apolipoprotein E (apoE) E2/E2 phenotype in all patients.
- Two patients had partial or complete lipoprotein lipase (LPL) deficiency.
- One patient also had heterozygous familial hypercholesterolemia.
Implications:
- Type III HLP in children has severe, lifelong consequences, including premature vascular disease and recurrent pancreatitis.
- Early disease presentation may be linked to additional precipitating factors.
- Pharmacological treatment is indicated for pediatric Type III HLP when dietary changes are insufficient.
Abstract:
Type III hyperlipoproteinemia (type III HLP) rarely manifests in childhood. Long-term follow-up (37 years) of the first patient revealed hypothyroidism at diagnosis requiring thyroxine replacement, palmar xanthomas requiring surgical removal, splenomegaly requiring splenectomy, 18 episodes of pancreatitis and premature coronary artery disease. Investigation revealed an apolipoprotein E phenotype of E2/E2 and partial lipoprotein lipase deficiency. Investigation of the second patient revealed a combination of apoE2/E2 phenotype and heterozygous familial hypercholesterolaemia. The third patient had a complete deficiency of lipoprotein lipase activity, an abnormal thyroid stimulating hormone on diagnosis (with subsequent normalisation without treatment), and apoE2/E2 phenotype. Type III HLP is a serious disorder with lifelong consequences of premature vascular disease and recurrent pancreatitis. Early presentation of disease in our patients was associated with additional precipitating factors. Drug treatment of paediatric type III HLP is indicated if dietary modifications alone are insufficient in managing the dyslipidaemia.
Related Concept Videos
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Type I Diabetes III: Clinical Manifestations
Inborn Errors of Metabolism
Type I Diabetes II: Pathophysiology
Type I Diabetes I: Introduction
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
